Yes Migy119 - it will or might get way worst before they get better revenues.
This is the hard reality points:
- we are in a risk averse period,
- Biotechs are high risk segments to begin with,
- Revenue is key to any company, let alone OSX - they are below par at this stage, so they have a very low fair value
- They have low to no cash, further dilution is possible. Investors know this.
Until they show revenue growth, all their prospects are fluff talk. It might work out - but we have to wait for a few years and track them.
Ann: MOU with Temasek-linked Innoventures - Orthopaedics in China, page-30
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.013M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.1¢ | 1.0¢ | $2.199K | 203.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 1342180 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 30414 | 1 |
View Market Depth
| Last trade - 10.42am 26/06/2025 (20 minute delay) ? |
| OSX (ASX) Chart |